Bortezomib enhances radiosensitivity in oral cancer through inducing autophagy-mediated TRAF6 oncoprotein degradation
Authors:
Open Access
- 27 April 2018
- journal article
- research article
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 37 (1) , 1-14
Abstract
Oral squamous cell carcinoma (OSCC) is a malignant tumor that may occur anywhere within the oral cavity. The survival rate of OSCC patients has not improved over the past decades due to its heterogeneous etiology, genetic aberrations, and treatment outcomes. We investigated the role of tumor necrosis factor receptor-associated factor 6 (TRAF6) in OSCC cells treated with bortezomib (a proteasome inhibitor) combined with irradiation (IR) treatment. The effects of combined treatment in OSCC cells were investigated using assays of cell viability, autophagy, apoptosis, western blotting, and immunofluorescence staining. The ubiquitination of proteins was analyzed by immunoprecipitation. Stable knockdown of TRAF6 in OSCC cells was constructed with lentivirus. The xenograft murine models were used to observe tumor growth. We found synergistic effects of bortezomib and IR on the viability of human oral cancer cells. The combination of bortezomib and IR treatment induced autophagic cell death. Furthermore, bortezomib inhibited IR-induced TRAF6 ubiquitination and inhibited TRAF6-mediated Akt activation. Bortezomib reduced TRAF6 protein expression through autophagy-mediated lysosomal degradation. TRAF6 played an oncogenic role in tumorigenesis of human oral cancer cells and oral tumor growth was suppressed by bortezomib and IR treatment. In addition, OSCC patients with expression of TRAF6 showed a trend towards poorer cancer-specific survival when compared with patients without TRAF6 expression. A combination of a proteasome inhibitor, IR treatment and TRAF6 inhibition could be a novel therapeutic strategy in OSCC.Keywords
Funding Information
- Medical Science and Technology Research Grant, National Cheng Kung University Hospital (NCKUH-10602004)
- Ministry of Science and Technology, Taiwan (MOST 106-2314-B-006-029-MY3, MOST 105-2320-B-038-021-MY3)
- Chi Mei Medical Center, Tainan, Taiwan
This publication has 45 references indexed in Scilit:
- Targeting autophagy in cancerNature Reviews Cancer, 2017
- The emerging complexity of ubiquitin architectureThe Journal of Biochemistry, 2016
- Expression and Clinical Significance of Tumor Necrosis Factor Receptor-Associated Factor 6 in Patients With Colon CancerIranian Red Crescent Medical Journal, 2016
- TRAF6 promoted the metastasis of esophageal squamous cell carcinomaTumor Biology, 2013
- BAK and NOXA Are Critical Determinants of Mitochondrial Apoptosis Induced by Bortezomib in MesotheliomaPLOS ONE, 2013
- A Cytoplasmic ATM-TRAF6-cIAP1 Module Links Nuclear DNA Damage Signaling to Ubiquitin-Mediated NF-κB ActivationMolecular Cell, 2010
- Combination treatment with arsenic trioxide and irradiation enhances cell-killing effects in human fibrosarcoma cells in vitro and in vivo through induction of both autophagy and apoptosisAutophagy, 2010
- Chapter 5 Autophagic Clearance of Aggregate‐Prone Proteins Associated with Neurodegeneration2009
- Bortezomib Inhibits Nuclear Factor-κB–Dependent Survival and Has Potent In vivo Activity in MesotheliomaClinical Cancer Research, 2007
- Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cellsCell Death & Differentiation, 2004